Clinical trial · Observational
Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers Diagnosis
Plasma Extracellular Vesicle Quantitative Proteomic Analysis for Early Diagnosis of Upper Gastrointestinal Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study constitutes a case-control investigation employing a retrospective approach. Plasma samples from individuals with esophageal cancer, benign esophageal diseases, gastric cancer, benign gastric diseases, and a healthy control group were systematically collected. Advanced Data-Independent Acquisition (DIA) proteomics and single-vesicle membrane protein detection techniques were employed to quantify protein content within exosomes. Specific protein biomarkers indicative of early-stage upper gastrointestinal tumors were identified. External validation of these protein markers was conducted using Parallel Reaction Monitoring (PRM) technology on an independent validation cohort. The objective is to establish protein marker predictions for early diagnosis of upper gastrointestinal tumors and prognostication of therapeutic efficacy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophagus Cancer | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Esophagus Cancer | Other | — | UNRESOLVED |
| Gastric Cancer | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Gastric cancer group
- description
- Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
- interventionNames
- Other: Gastric Cancer
- label
- esophagus cancer group
- description
- Patients diagnosed with esophagus cancer, including early esophagus cancer and advanced esophagus cancer
- interventionNames
- Other: Esophagus Cancer
- label
- Non-cancer group
- description
- Patients diagnosed with benign upper gastrointestinal diseases or healthy controls
Primary outcomes (2)
- measure
- Plasma proteins in patients with gastric cancer
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of upper gastrointestinal cancers or benign upper gastrointestinal diseases through gastroscopy and pathological examination. * Collection of plasma samples prior to surgical treatment. * Availability of complete clinical data. Exclusion Criteria: * Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection. * Coexistence of other systemic tumors. * Absence of plasma sample collection before surgical treatment. * Incomplete clinical data. * Pregnancy status
References
Publications (0)
Data not yet available